Vascular Solutions, Inc. (NASDAQ:VASC) has been downgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 2, 2016
Yesterday Vascular Solutions, Inc. (NASDAQ:VASC) traded 1.64% higher at $48.63. The company’s 50-day moving average is $48.44 and its 200-day moving average is $40.98. The last stock close price is up 17.70% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 124,436 shares of the stock were exchanged, up from an average trading volume of 116,616
Zacks Investment Research has downgraded Vascular Solutions, Inc. (NASDAQ:VASC) to Hold in a report released on 09/28/2016.
Previously on Wednesday July 22, 2015, Canaccord Genuity reported about Vascular Solutions, Inc. (NASDAQ:VASC) raised the target price from $37.00 to $41.00. At the time, this indicated a possible upside of 0.04%.
See Chart Below
Vascular Solutions, Inc. has a price-earnings ratio of 89.31 with a one year low of $24.34 and a one year high of $50.72 VASC’s total market value is presently $0.
More About Vascular Solutions, Inc. (NASDAQ:VASC)
Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.